Literature DB >> 31832702

Interventional therapy in malignant conditions of the prostate.

Attila Kovács1, Michael Pinkawa2.   

Abstract

Interventional therapies are emerging modalities for the treatment of localized prostate cancer. Their aim is to reduce the morbidity associated with radical therapies (rT) by minimizing damage to non-cancerous tissue, with priority given to sparing key structures such as the neurovascular bundles, external sphincter, bladder neck, and rectum, while maintaining local cancer control. Interventional ablative technologies deliver energy in different ways to destroy cancer cells. The most widely investigated techniques are brachytherapy, external beam radiotherapy, cryotherapy, and high-intensity focused ultrasound. Although functional outcomes of focal therapies have been encouraging, with generally low rates of urinary incontinence and erectile dysfunction, robust medium- and long-term oncological outcomes are not available for all techniques. To date, major controversies in focal therapy concern appropriate patient selection, efficacy of focal therapies, as well as treatment paradigms based on the dominant index lesion hypothesis. This review articles discusses the current status of interventional therapies and the oncological and functional outcomes.

Entities:  

Keywords:  Brachytherapy; Cryotherapy; External beam radiation therapy; High-intensity focused ultrasound; Prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31832702     DOI: 10.1007/s00117-019-00632-x

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  69 in total

1.  NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

Authors:  Peter R Carroll; J Kellogg Parsons; Gerald Andriole; Robert R Bahnson; Erik P Castle; William J Catalona; Douglas M Dahl; John W Davis; Jonathan I Epstein; Ruth B Etzioni; Thomas Farrington; George P Hemstreet; Mark H Kawachi; Simon Kim; Paul H Lange; Kevin R Loughlin; William Lowrance; Paul Maroni; James Mohler; Todd M Morgan; Kelvin A Moses; Robert B Nadler; Michael Poch; Chuck Scales; Terrence M Shaneyfelt; Marc C Smaldone; Geoffrey Sonn; Preston Sprenkle; Andrew J Vickers; Robert Wake; Dorothy A Shead; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2016-05       Impact factor: 11.908

2.  The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.

Authors:  Timothy J Wilt
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

Review 3.  Focal therapy for prostate cancer: possibilities and limitations.

Authors:  Scott Eggener; Georg Salomon; Peter T Scardino; Jean De la Rosette; Thomas J Polascik; Simon Brewster
Journal:  Eur Urol       Date:  2010-03-26       Impact factor: 20.096

4.  Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data.

Authors:  Kae Jack Tay; Thomas James Polascik; Ahmed Elshafei; Efrat Tsivian; J Stephen Jones
Journal:  J Endourol       Date:  2017-06       Impact factor: 2.942

5.  Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.

Authors:  György Kovács; Klaudia Müller; Tamer Soror; Corinna Melchert; Xiyuan Guo; Dieter Jocham; Axel Merseburger
Journal:  Brachytherapy       Date:  2016-12-07       Impact factor: 2.362

Review 6.  Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?

Authors:  G C Morton; P J Hoskin
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-05-30       Impact factor: 4.126

7.  The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.

Authors:  W van den Bos; D M de Bruin; B G Muller; I M Varkarakis; A A Karagiannis; P J Zondervan; M P Laguna Pes; D P Veelo; C D Savci Heijink; M R W Engelbrecht; H Wijkstra; T M de Reijke; J J M C H de la Rosette
Journal:  BMJ Open       Date:  2014-10-29       Impact factor: 2.692

8.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079

Review 9.  Focal therapy for prostate cancer: rationale and treatment opportunities.

Authors:  V Kasivisvanathan; M Emberton; H U Ahmed
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-06-04       Impact factor: 4.126

10.  Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trials.

Authors:  Gregory S Merrick; Ava Tennant; Kent E Wallner; Robert Galbreath; Wayne M Butler; Ryan Fiano; Edward Adamovich
Journal:  J Contemp Brachytherapy       Date:  2017-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.